Next Generation Sequencing in Non-Small Cell Lung Cancer: Pitfalls and Opportunities

被引：24

作者：

Lazzari, Chiara ^{[1
]}

Bulotta, Alessandra ^{[1
]}

Cangi, Maria Giulia ^{[2
]}

Bucci, Gabriele ^{[3
]}

Pecciarini, Lorenza ^{[2
]}

Bonfiglio, Silvia ^{[3
]}

Lorusso, Vincenza ^{[1
,2
]}

Ippati, Stefania ^{[1
]}

Arrigoni, Gianluigi ^{[2
]}

Grassini, Greta ^{[2
]}

Doglioni, Claudio ^{[2
]}

Gregorc, Vanesa ^{[1
]}

机构：

[1] IRCCS San Raffaele, Dept Oncol, I-20132 Milan, Italy

[2] IRCCS San Raffaele, Dept Pathol, I-20132 Milan, Italy

[3] IRCCS San Raffaele, Ctr Omics Sci, I-20132 Milan, Italy

来源：

DIAGNOSTICS | 2020年 / 10卷 / 12期

关键词：

non-small cell lung cancer; next-generation sequencing; molecular tumor board; BIOLOGY; DRUGS;

D O I：

10.3390/diagnostics10121092

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Lung cancer remains the first cause of cancer-related deaths worldwide. Thanks to the improvement in the knowledge of the biology of non-small cell lung cancer (NSCLC), patients' survival has significantly improved. A growing number of targetable molecular alterations have been identified. Next-generation sequencing (NGS) has become one of the methodologies entered in clinical practice and was recently recommended by the European society for medical oncology (ESMO) to perform a comprehensive molecular characterization in patients with cancer. The current review provides an overview of the clinical trials that have explored the impact of NGS in patients with cancer, its limits, and advantages.

引用

页数：12

共 33 条

[1] SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy) [J].

Aggarwal, Charu ;

Redman, Mary W. ;

Lara, Primo N., Jr. ;

Borghaei, Hossein ;

Hoffman, Philip ;

Bradley, Jeffrey D. ;

Newman, Alfred J., III ;

Feldman, Marvin J. ;

Minichiello, Katherine ;

Miao, Jieling ;

Mack, Philip C. ;

Papadimitrakopoulou, Vassiliki A. ;

Herbst, Roy S. ;

Kelly, Karen ;

Gandara, David R. .

JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) :1847-1852

[2] Palbociclib in Patients With Non-Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study [J].

Ahn, Eugene R. ;

Mangat, Pam K. ;

Garrett-Mayer, Elizabeth ;

Halabi, Susan ;

Dib, Elie G. ;

Haggstrom, Daniel E. ;

Alguire, Kathryn B. ;

Calfa, Carmen J. ;

Cannon, Timothy L. ;

Crilley, Pamela A. ;

Gaba, Anu G. ;

Marr, Alissa S. ;

Sangal, Ashish ;

Thota, Ramya ;

Antonelli, Kaitlyn R. ;

Islam, Samiha ;

Rygiel, Andrew L. ;

Bruinooge, Suanna S. ;

Schilsky, Richard L. .

JCO PRECISION ONCOLOGY, 2020, 4 :757-766

[3]

[Anonymous], 2016, BIOMARKER TESTS MOL

[4] Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) [J].

Barlesi, Fabrice ;

Mazieres, Julien ;

Merlio, Jean-Philippe ;

Debieuvre, Didier ;

Mosser, Jean ;

Lena, Herve ;

Ouafik, L'Houcine ;

Besse, Benjamin ;

Rouquette, Isabelle ;

Westeel, Virginie ;

Escande, Fabienne ;

Monnet, Isabelle ;

Lemoine, Antoinette ;

Veillon, Remi ;

Blons, Helene ;

Audigier-Valette, Clarisse ;

Bringuier, Pierre-Paul ;

Lamy, Regine ;

Beau-Faller, Michele ;

Pujol, Jean-Louis ;

Sabourin, Jean-Christophe ;

Penault-Llorca, Frederique ;

Denis, Marc G. ;

Lantuejoul, Sylvie ;

Morin, Franck ;

Quan Tran ;

Missy, Pascale ;

Langlais, Alexandra ;

Milleron, Bernard ;

Cadranel, Jacques ;

Soria, Jean-Charles ;

Zalcman, Gerard .

LANCET, 2016, 387 (10026) :1415-1426

[5]

Chakravarty Debyani, 2017, JCO Precis Oncol, V2017, DOI 10.1200/PO.17.00011

[6] Cumulative Haploinsufficiency and Triplosensitivity Drive Aneuploidy Patterns and Shape the Cancer Genome [J].

Davoli, Teresa ;

Xu, Andrew Wei ;

Mengwasser, Kristen E. ;

Sack, Laura M. ;

Yoon, John C. ;

Park, Peter J. ;

Elledge, Stephen J. .

CELL, 2013, 155 (04) :948-962

[7] MuSiC: Identifying mutational significance in cancer genomes [J].

Dees, Nathan D. ;

Zhang, Qunyuan ;

Kandoth, Cyriac ;

Wendl, Michael C. ;

Schierding, William ;

Koboldt, Daniel C. ;

Mooney, Thomas B. ;

Callaway, Matthew B. ;

Dooling, David ;

Mardis, Elaine R. ;

Wilson, Richard K. ;

Ding, Li .

GENOME RESEARCH, 2012, 22 (08) :1589-1598

[8] Database of Genomic Biomarkers for Cancer Drugs and Clinical Targetability in Solid Tumors [J].

Dienstmann, Rodrigo ;

Jang, In Sock ;

Bot, Brian ;

Friend, Stephen ;

Guinney, Justin .

CANCER DISCOVERY, 2015, 5 (02) :118-123

[9] SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy) [J].

Edelman, Martin J. ;

Redman, Mary W. ;

Albain, Kathy S. ;

McGary, Eric C. ;

Rafique, Noman M. ;

Petro, Daniel ;

Waqar, Saiama N. ;

Minichiello, Katherine ;

Miao, Jieling ;

Papadimitrakopoulou, Vassiliki A. ;

Kelly, Karen ;

Gandara, David R. ;

Herbst, Roy S. .

JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) :1853-1859

[10] Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study [J].

Fisher, Julie G. ;

Tait, David ;

Garrett-Mayer, Elizabeth ;

Halabi, Susan ;

Mangat, Pam K. ;

Schink, Julian C. ;

Alvarez, Ricardo H. ;

Veljovich, Dan ;

Cannon, Timothy L. ;

Crilley, Pamela A. ;

Pollock, Theodore ;

Calfa, Carmen J. ;

Al Baghdadi, Tareq ;

Thota, Ramya ;

Fleming, Nicole ;

Cotta, Jared A. ;

Rygiel, Andrew L. ;

Warren, Sasha L. ;

Schilsky, Richard L. .

TARGETED ONCOLOGY, 2020, 15 (06) :733-741

← 1 2 3 4 →